Rethinking the Hydroxychloroquine Rulebook for Lupus
A new perspective in Arthritis & Rheumatology challenges the rigid adherence to a 5 mg/kg weight-based dosing cutoff for hydroxychloroquine in systemic lupus erythematosus (SLE). The article suggests that optimizing this cornerstone DMARD therapy may require looking beyond this conventional threshold to better balance efficacy against the risk of retinal toxicity. This commentary highlights an ongoing debate in rheumatology about personalizing treatment strategies for autoimmune diseases to improve patient outcomes.
Why it might matter to you: This discussion directly impacts clinical decision-making for a fundamental SLE therapy. For rheumatologists, it underscores the need to critically evaluate standard dosing paradigms and consider more nuanced, patient-specific approaches to using conventional DMARDs. Staying informed on this debate is crucial for optimizing treatment protocols and managing the long-term safety of patients with autoimmune conditions.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
